Adaptive Biotechnologies Corporation CEO, Chad Robins, highlights today the companies’ work in cancer immunotherapy at the “What’s Hot in Cancer Immunotherapy” event hosted by Xconomy at the Fred Hutchinson Cancer Research Center.
Adaptive Biotechnologies, a Seattle startup that focuses on scouring the genetic makeup of the immune system to help fight cancer and other diseases, said Monday it has raised an eye-popping $105 million in funding to boost its research and commercial efforts. Read full article at Times Website
Adaptive announced today the completion of the Company’s Series C financing round and the completion of a newly created Series D round with a $105 million investment from Viking Global Investors. This investment will enable the Company to expand globally its preeminent immunosequencing research platform and downstream validated clinical diagnostic products.
Adaptive CEO Chad Robins speaking today at “The Future of Healthcare in Washington” conference beginning at 1PM. His talk is titled “How Genomics is Enabling Diagnostics that will Change Clinical Practice.”
Julie Rubinstein, Adaptive’s SVP of Business Development, will speak at Bloomberg’s State of Health Care 2014 Conference in New York City. She will participate on an expert panel entitled Innovation in Healthcare, which will feature the growth and promise of cancer immunotherapy.
Adaptive announced today that Peter Neupert and Rob Rosen (pictured at left) will join its Board of Directors to strengthen its healthcare distribution system and software expertise and to add the financial experience necessary for commercialization.
Adaptive announced today a biomarker discovery agreement facilitated by the Johnson & Johnson Innovation Center in California. Under the agreement, Adaptive will use its patented immune profiling assay, immunoSEQTM, to enable an in-depth characterization of the immune response to diseases being studied and select immunology and oncology drugs being developed by Janssen Research & Development, LLC (Janssen). The exploration of immune response may identify patient populations more likely to respond to targeted therapies based on their immune status.
Adaptive announced today that Chad Robins, Founder and Chief Executive Officer, is scheduled to present a company overview at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 15th, 2014 at 2:00pm PST.
CBS News just published a story highlighting the promise of Adaptive’s QuanTILfy test that is being tested in many solid tumors for the prognosis, diagnosis, and monitoring of cancer patients. The article is based on a study published yesterday in Science Translational Medicine demonstrating that QuanTILfy may help predict survival in ovarian cancer patients.
Adaptive and its collaborators will present data demonstrating how immunosequencing can inform survival in patients with blood cancers at the American Society of Hematology (ASH) meeting from December 7-10, 2013.